This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Editas (EDIT) in Focus: Stock Moves 8.6% Higher
by Zacks Equity Research
Editas (EDIT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Editas (EDIT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y
by Zacks Equity Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
Editas Medicine (EDIT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 11.54% and -3.82%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Editas Medicine (EDIT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Editas Medicine (EDIT) stock based on the movements in the options market lately.
Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Editas, Allergan Start Dosing in Early-Stage Eye Disease Study
by Zacks Equity Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates
by Zacks Equity Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of -311.43% and -75.75%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Editas (EDIT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Editas (EDIT) stock based on the movements in the options market lately.
Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
by Zacks Equity Research
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.
Editas Medicine (EDIT) Is Up 6.66% in One Week: What You Should Know
by Zacks Equity Research
Does Editas Medicine (EDIT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher
by Zacks Equity Research
Editas Medicine (EDIT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data
by Zacks Equity Research
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
by Zacks Equity Research
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Editas Medicine
by Zacks Equity Research
Editas Medicine, Inc. (EDIT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Editas Inks Deal for Gene Editing Neurological Disease Drugs
by Zacks Equity Research
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
CRISPR Therapeutics Enters New License Agreement, Shares Up
by Zacks Equity Research
CRISPR Therapeutics (CRSP) looks to strengthen its CAR-T therapy programs through its agreement with KSQ Therapeutics.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.